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Integrin binding to bioengineered hydrogel scaffolds is essential for tissue regrowth and 
regeneration, yet not all integrin binding can lead to tissue repair. Here, we show that through 
engineering hydrogel materials to promote α3/α5β1 integrin binding, we can promote the 
formation of a space filling and mature vasculature compared to hydrogel materials that promote a 
αvβ3 integrin binding. In vitro, α3/α5β1 scaffolds promoted endothelial cells to sprout and 
branch, forming organized extensive networks that eventually reached and anastomosed with 
neighboring branches. In vivo, α3/α5β1 scaffolds delivering vascular endothelial growth factor 
(VEGF) promoted non-tortuous blood vessel formation and non-leaky blood vessels by 10-days 
post stroke. In contrast, materials that promote αvβ3 integrin binding promoted endothelial sprout 
clumping in vitro and leaky vessels in vivo. This work shows that precisely controlled integrin 
activation from a biomaterial can be harnessed to direct therapeutic vessel regeneration and reduce 
VEGF induced vascular permeability in vivo.
The design of therapeutic angiogenic materials to treat cardiovascular diseases, such as 
deficient blood supply to the heart, limbs, and brain, has primarily been driven by the 
delivery of angiogenic factors within a scaffold. Recently, the synergy between extracellular 
matrix (ECM) integrin ligands and angiogenic factor delivery has been demonstrated 1 and 
proposed as a therapeutic strategy to design next generation agiogneic materials 2. However, 
specific integrin engagement from engineered materials has not been explored as a vascular 
morphogenic signal.
Integrins are a family of heterodimeric transmembrane proteins, composed of alpha (α) and 
beta (β) subunits, that bind to both the extracellular matrix (ECM) and the cellular 
cytoskeleton, providing both mechanical and biochemical signaling3. Integrins have been 
associated with processes ranging from cell structure and adhesion to cell differentiation and 
survival3–5, which are cell behaviors critical to tissue morphogenesis, homeostasis and 
repair. In endothelial cells, at least seven α and β heterodimers are expressed, including 
αvβ3, α3β1 and α5β1, which have been implicated in vascular morphogenesis and vessel 
patterning 6, 7. In particular, β1 and β3 integrins have been implicated in vascular lumen 
formation6, 8, tight cell-cell junction formation6, 9, 10, and the recruitment of mural cells to 
the vessels for stabilization11. β1 integrin expression is slowly upregulated in brain vessels 
over time as vessels mature12 and αvβ3 expression in resting endothelial cells (ECs) is low, 
while αvβ3 expression in cytokine-activated ECs or tumor ECs is upregulated 13–15. Further, 
both up-regulation and abolishment of β1 and β3 integrin activation have shown to be 
related to pathological angiogenesis3, 9, 10, 16, 17. While excessive suprabasal expression of 
β1 integrin in skin has been shown to induce a psoriasis phenotype16, the knockout of β1 
integrin resulted in weakening of endothelial cell junctions and induction of blood leakage in 
a retinal angiogenesis assay9. Likewise, the upregulation of β3 integrin leads to enhanced 
endothelial cell permeability18 while the abolition of β3 integrin leads to intrauterine 
bleeding, defective coronary capillaries, and enhanced tumor angiogenesis (induced by the 
compensatory VEGF increase after β3 knockout)10, 17, 19.
The incorporation of integrin binding peptides such as RGD derived from natural ECM 
proteins to biomaterials is a popular approach to promote integrin engagement20–22. Though 
integrin-binding peptides can support cell attachment, migration, and differentiation, they 
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have severely reduced binding affinity and specificity compared to the same peptide 
presented within its associated full-length 3D protein structure. In the context of fibronectin 
(Fn), recombinant fragments of the 9th type III repeat and 10th type III repeat (Fn III9-10) 
have been expressed and incorporated into matrices to present RGD sequences in their 
correct 3D structural context to improve binding affinity and modulate growth factor 
signaling 1. However, without the rest of the full-length protein these protein fragments do 
not contain the natural switches that modulate integrin engagement (e.g. native fibronectin 
binds several integrin pairs depending on the level of extension of the protein23, 24) and thus, 
lack complete specificity. To improve specificity, recombinant fragments of Fn III9-10 have 
been engineered to promote α3/α5β1 specific binding, enhanced mesenchymal stem cell 
differentiation toward bone25, and modulation of epithelial to mesenchymal transition26. 
Here we explore specific integrin engagement as a vascular morphogenic signal within 
engineered matrices.
Fibronectin fragments with tunable integrin binding
Immediately following injury, fibrin and fibronectin are the major ECM constituents of the 
provisional pre-vascularized matrix. In our study, recombinant fibronectin fragments of Fn 
III9-10 were designed to preferentially bind α3/α5β1 or αvβ3 integrin through introduction 
of a Leu-Pro point mutation at position 1408 or a flexible linker (4XGly) spanning between 
to the two domains 25, 27, 28. Though both recombinant fragments can bind αvβ3 integrin via 
the RGD sequence, we and others consistently observe a preference of the Leu-Pro mutant 
to bind synergy-dependent integrins, like α5β1 integrin in cell – material interactions26, 29. 
In this manuscript, we refer to the Leu-Pro mutated, or stabilized, fragment as 9*10 and the 
4xGly insertion mutated fragment as 9(4G)10. For ease of immobilization onto surfaces and 
incorporation into natural and synthetic hydrogel biomaterials both fragments were 
produced with an N-terminal cysteine residue to allow Michael type addition modifications 
and a factor XIIIa substrate sequence 30 to allow enzymatic conjugation.
Fibronectin fragment coated surfaces were first used to verify the specific integrin 
activations on human umbilical vein endothelial cells (HUVEC). HUVEC were able to 
attach and spread on either fragment-modified surface (Fig. S1a-c). As expected, clear αvβ3 
integrin staining was observed on Fn9(4G)10 coated surfaces but not Fn9*10 coated 
surfaces, while clear β1 integrin staining was observed at cell edges on Fn9*10 coated 
surfaces but not on the Fn9(4G)10 coated ones (Fig. S1a). The actin cytoskeleton for cells 
cultured on αvβ3 specific Fn9(4G)10 surfaces showed more short and disoriented actin 
fibers compared with α3/α5β1 specific Fn9*10 surfaces, where actin fibers reached 
extensive lengths (Fig. S1c), suggesting that differential integrin activation from 
immobilized fragments impacts EC cytoskeleton arrangement in 2D. Addition of VEGF to 
ECs plated on αvβ3 specific surfaces significantly increased EC migration compared to cells 
seeded on blank surfaces or α3/α5β1 specific surfaces, while no differences were observed 
for EC proliferation or integrin binding (Fig S1. d-f). Together these findings confirm that 
ECs alter their cellular behavior depending on the integrin binding specificity dominating 
their attachment to the surface.
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Integrin stimulation guides endothelial cell sprouting patterns
We are interested in using VEGF, the master regulator of angiogenesis31, to induce EC 
sprouting and angiogenesis in vivo. Thus, we looked at the influence of fibronectin mediated 
cell adhesion on VEGF induced vascular sprouting in a three-dimensional assay. Two types 
of commercially available fibrinogen were used, one that contained fibronectin (Fib1) and 
one that is fibronectin depleted (Fib3). EC coated beads were suspended in the fibrin 
matrices and cultured in the presence of soluble VEGF for 7-days following the protocol of 
Hughes et al (Fig. S2a)32. At day 7, the cultures were fixed, stained for actin, and quantified 
for the number of sprouts, number of branching points and total network length per bead. 
Sprouting and branching points in Fib3 was significantly decreased compared with Fib1, 
suggesting that the presence of native fibronectin is critical for EC sprouting (Fig. 1a and 
Fig. S2b). Addition of exogenous fibronectin to Fib3 partially rescued EC sprouting, 
resulting in statistically increased sprouting, branching points and total network length (Fig. 
S2b); however, regardless of the amount of exogenous fibronectin added, the level of 
sprouting in Fib3 was significantly lower than that observed in Fib1 (Fig. 1a,b and Fig. S2b). 
This indicated that besides the endogenous fibronectin within the Fib1 matrices, other 
factors removed during the Fib3 preparation may also be important for EC sprouting in 
fibrin. Among all the tested fibronectin concentrations, it was also observed that 1μM was 
the lowest concentration that achieved statistically increased sprouting, branching points and 
total network length (Fig. S2b). Thus, we incorporated equal molar concentration of Fn 
III9-10 fragments (2μM), in our in vitro studies; each fibronectin protein contains two copies 
of Fn III9-10.
We next tested the role of α3/α5β1-specific (Fn9*10 fragment added) and αvβ3-specific 
(Fn9(4G)10 fragment added) matrices on EC sprouting. The number of sprouts, branch 
points or total network length showed no significant difference among full length 
fibronectin, α3/α5β1-specific and αvβ3-specific conditions, indicating that integrin 
engagement is a major factor that affects sprouting (Fig. 1b,c and Fig. S2c). Between α3/
α5β1-specific and αvβ3-specific conditions we observed no differences in sprout number, 
branch points or total network length (Fig. 1b-e, Fig. S2c,d and Fig. S3a-c,e-g); however, we 
observed sprouting “clusters” in the αvβ3-specific matrices but not on blank, fibronectin, or 
α3/α5β1-specific matrices (Fig. 1a,f). The clusters are merged vessel branch clumps from 
the same bead, which can either locate close to the surface of the beads or on the sprouts. 
They are always presented as chaotic branch bundles, thus the number of branches and 
sprouts within them are difficult to discern. Using high resolution z-stack confocal imaging 
we found that the clusters were associated with intra-loop and intra-joint structures both 
within and between neighboring sprouts, which were not observed in α3/α5β1-specific 
matrices (Fig. 1f). The quantification of the number of clusters per bead, sprout or branch, 
showed statistically significant occurrence in αvβ3-specific gels compared with the blank, 
fibronectin and α3/α5β1-specific Fib1 or α3/α5β1-specific Fib3 matrices (Fig. 1g,h, Fig. 
S3d,h and Fig. S4a-f). Taken together, these results show that although both Fn fragments 
enhanced sprouting and branching of ECs, they lead to different vascular patterns in the 
resulting EC network. In particular, αvβ3-specific matrices promoted the formation of a 
pathological vascular network33 containing intra-loop and intra-joint features.
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The involvement and importance of integrins in EC sprouting was further confirmed through 
function blocking antibody studies. VEGF induced EC sprouting in α3/α5β1-specific 
matrices in the presence of function blocking antibodies against either α5 or β1 completely 
inhibited the sprouting process (Fig. 2a and Fig. S4g,h). In contrast, EC sprouting in αvβ3-
specific matrices in the presence of function blocking antibodies against αv did not impact 
sprouting, while function blocking antibodies against β3 again completely inhibited the 
sprouting process (Fig. 2a and Fig. S4g,h). These results indicate that α5, β3, and β1 are 
essential to EC sprouting but αv is not. We next explored whether blocking αv normalized 
the resulting vasculature by decreasing the number of intra-loop and intra-joint structures. 
Surprisingly, blocking αv binding decreased the number of branch clusters (Fig. 2b), 
suggesting that αv binding is responsible for the sprout clusters formed in the αvβ3-specific 
matrices. These results are in agreement with previous studies showing that activation of 
αvβ3 results in increased vascular permeability in 2D18 while inhibition of αv reduces 
vascular permeability34. Interestingly, we have recently demonstrated in a retinal 
angiogenesis model that tips cells mechanically unfold the integrin binding domain of Fn at 
their leading edge, resulting in a Fn9(4G)10 and thus avb3 binding character. The 
conformation of Fn’s integrin binding domain returns to its native, Fn9*10-like 
conformation during vessel maturation 35
Matrices modified with RGD peptides show similar vascular pattern as 
Fn9(4G)10
Next, we sought to examine vascular patterns utilizing the ubiquitously used synthetic 
peptide derived from fibronectin, RGD. RGD peptides with α2PI1-8 sequences (H-
NQEQVSPLRGDSPG-NH2) were incorporated within fibrin matrices using FXIIIa enzyme. 
As observed with the fibronectin fragments, the incorporation of RGD within Fib3 matrices 
resulted in enhanced EC sprouting (Fig. 2c-e and Fig. S4i,j). Similar to αvβ3-specific 
matrices, RGD modified hydrogels resulted in intra-loop and intra-joint structures (Fig. 
2c,f). These results suggest that RGD binding without the presence of the proline-histidine-
serine-arginine-asparagine (PHSRN) “synergy” domain on the 9th type III repeat36, 37, result 
in pathological angiogenesis, which may come from the preferential αvβ3 binding38. It 
should be noted that the effect of enhanced sprouting and disorganized structures was only 
observed for a much higher concentration of RGD peptide (> 500μM) compared with the 
concentration of fibronectin fragments used (2μM).
Upregulation of αvβ3 and alterations in its activation state have been associated with disease 
states such as cancer39 and fibrosis40 and have been widely used as cancer targeting ligands 
in drug delivery applications41, yet RGD is the most widely used integrin binding peptide to 
modify biomaterials. We do not mean to suggest that the use of RGD modified biomaterials 
for therapeutic angiogenesis is inherently flawed; rather, we believe that the incorporation 
conditions for RGD peptides such as presentation, concentration, and other neighboring 
ligands should be studied to ensure that the desired revascularization pattern is obtained. For 
example, clustering RGD within hydrogels has been shown to upregulate the expression of 
β1 integrins in MSCs 42 and immobilization of VEGF has leads to β1 recruitment43.
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Integrin stimulation guides vascular anastomosis
During the angiogenesis process, sprouts from parental vessels fuse with other sprouts or 
pre-existing blood vessels for the purposes of supplying blood and oxygen to surrounding 
tissues44. To test the effect of αvβ3 and α3/α5β1 specific matrices on EC sprout 
anastomosis, a similar bead assay was performed using stably transfected ECs expressing 
enhanced green fluorescent protein (EGFP) (Fig. S5a). HDFs were seeded within the fibrin 
matrix to yield more robust and long-lasting tubes for culture. Normal anastomosis results in 
the binding of tip cells through a single contact45. Clear single tip-tip contact or paralleled 
tip interaction were observed in Fib3 and Fib3 + Fn9*10 conditions (Fig. S5b,c). In contrast, 
Fib3 + Fn9(4G) matrices promoted multiple tip-tip contacts, resulting in independent contact 
sites and loop structures (Fig. S5b,c). Thus, consistent with our observations in EC sprouting 
morphogenesis, inter-loop and inter-joint structures are observed in anastomosed sprouts 
within αvβ3-specific matrices.
αv activation leads to pathological vasculature through VE-cadherin 
disruption
Next, we investigated possible mechanisms for the observed differences in the vascular 
patterns generated by α3/α5β1-specific and αvβ3-specific matrices. Vessel sprouts lacking 
VE-cadherin display irregular anastomosis, characterized by multiple tip-tip contact sites 
and disturbed junctional connections45, similar to our observations in Fn9(4G)10 matrices. 
We examined VE-cadherin distribution on ECs cultured in vitro on αvβ3 or α3/α5β1 
modified surfaces. Cells seeded on α3/α5β1 specific surfaces showed significantly increased 
amounts of VE-cadherin signal at cell-cell junctions compared with αvβ3 specific 
conditions both with and without VEGF (Fig. 3a,b and Fig. S6a). Obvious absence and 
significantly lowered VE-cadherin signals between adjacent cells were observed on αvβ3 
specific surfaces, indicating VE-cadherin disruption (Fig. 3a,b and Fig. S6a). VE-cadherin 
grey value analysis was performed on randomly-chosen cell-cell junctions from Fig. 3a. 
α3/α5β1 specific surfaces led to thicker VE-cadherin layers with stronger signal at cell-cell 
junction when compared with αvβ3 specific surfaces (Fig. 3c,d). EC sprouting in αvβ3 
specific matrices was also characterized by reduced VE-cadherin staining on sprout shunts 
and cell-cell junctions compared with EC sprouting in α3/α5β1 specific matrices (Fig. 3e). 
To confirm that increased αv integrin binding is responsible for the decrease in VE-cadherin 
staining, αv integrin binding was disrupted using function-blocking antibodies as previously 
done. VE-cadherin staining after αv blocking in αvβ3 specific fibrin matrices showed EC 
cells with increased VE-cadherin staining similar to what was observed in α3/α5β1 specific 
matrices, strongly suggesting that αv binding is responsible for the reduction in VE-cadherin 
localized at cell-cell junctions. The effect of αv blocking was observed in both Fib1 and 
Fib3 matrices (Fig. 3e and Fig. S6b,c). VE-cadherin is an important cell-cell junction protein 
responsible for shifting endothelial cell response to VEGF 46, but also functions to maintain 
low permeability of endothelial cell layers18. Partial knockout of VE-cadherin can lead to 
vascular instability and hemorrhages47. VE-cadherin function can be disrupted by 
upregulation of αvβ3 integrin, enhancing endothelial cell permeability18. Taken together, 
these findings support the idea that VE-cadherin-related pathological vasculature was caused 
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by αv activation in αvβ3 specific matrices and demonstrate that αv blockage can be utilized 
to rescue the pathological effects.
Integrin stimulation from a bioengineered matrix guides vascular patterns 
in vivo
The fibronectin fragments were tested in a modified matrigel plug assay that uses 
bioengineered hyaluronic acid (HA) hydrogels instead of matrigel to assess angiogenesis in 
mice (Fig 4a and Fig. S7a-d). HA hydrogels are formed through crosslinking HA molecules 
using Michael type addition chemistry between acrylamide groups introduced to the 
backbone of hyaluronic acid and dithiol crosslinker containing protease degradable 
peptides48. Fn fragments were also introduced to this protease degradable hydrogel matrix 
backbone to mediate integrin binding using the same Michael type chemistry through the 
cysteine in the fragment N-terminus. VEGF was incorporated into the system using a 
controlled release system based on single protein nanocapsules (nV) previously developed in 
our laboratory49 (Fig. S7e). Hydrogels containing fibronectin fragments and nV were 
implanted subcutaneously (Fig. S7c,f). Evaluation of isolectin perfused whole mount 
sections was performed 14-days after implantation using light sheet (Fig. S8a) and confocal 
microscopy (Fig. 4). HA hydrogels that do not contain fibronectin fragments (blk) resulted 
in the least vessel sprouting on the hydrogel surface and vessel infiltration within the 
hydrogel compared with fragment conditions and was similar to normal skin (Fig. 4b) even 
with the presence of nV, demonstrating that integrin binding is essential for angiogenesis to 
occur in vivo (Fig. 4c and Fig. S8b-d). HA hydrogels modified with either fibronectin 
fragment supported an angiogenic response and similar infiltration (Fig. S8); however, the 
morphology of the vessels on the gel surfaces was significantly different. The α3/α5β1 
specific HA gels (Fn9*10 immobilized) displayed non-tortuous vessels displaying similar 
features as the normal mouse vasculature (control) while αvβ3 specific gels displayed 
tortuous and unorganized vessels that appeared to clump with one another (Fig. 4b-d). While 
vessels on α5β1 specific gel surfaces presented organized and even vessel distribution like 
the blank gel control, vessels on αvβ3 specific gel surfaces yielded uneven distributions, 
which originated from regional tortuous and unorganized vessel clumps (Fig. 4e,f). These 
results show that similar to in vitro sprouting and anastomosis, integrin specific materials 
can dictate vascular patterning in vivo in a non-diseased model.
α3/α5β1 integrin binding reduces VEGF induced vascular permeability after 
stroke
We next sought to evaluate the angiogenic response of integrin specific materials on VEGF-
induced angiogenesis in a murine model of stroke. VEGF is one of the essential molecules 
in normal post-stroke angiogenesis 50. However, The delivery of VEGF after stroke, has 
been complicated by the induction of a disordered and permeable vasculature51, similar to 
other organs 52–54. Given that fibronectin is upregulated in the provisional matrix after 
stroke, but is only located in blood vessels in normal brain (Fig. 5a and Fig. S9a), we believe 
that the injection of an integrin specific hydrogel into the stroke cavity can modulate 
vascular patterning after stroke. Adult mice were submitted to a cerebral artery occlusion 
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(MCAo). 5-days after stroke, HA hydrogels (containing nV and fragments) were injected 
directly into the stroke cavity (Fig. 5b). Ten days post-transplantation, animals injected with 
fibronectin fragment containing hydrogels were perfused with tomato lectin before sacrifice 
for the purpose of studying perfused vessel morphology while other animals were directly 
perfused with 4% PFA and sacrificed.
Sections were all stained for Glut-1, a glucose transporter expressed on brain endothelial 
cells and the positively stained vascular area was quantified in both the infarct and peri-
infarct areas (Fig. 5c). To compare the vascular bed in all conditions, both Glut-1 stained 
only and Glut-1 plus tomato lectin stained in tomato lectin-perfused animals were 
quantified. Glut-1 stained for all vessels while tomato lectin only stained for perfused 
vessels. Tomato lectin alters Glut-1 staining such that in tomato lectin-perfused animals the 
combination of both stains reveals the vascular bed the same as Glut-1 alone in tomato 
lectin-unperfused animals (Fig. S9b). As expected, all the VEGF containing hydrogels 
showed a greater vascular area percentage than RGD only gels in the infarct and the peri-
infarct regions. However, we found that the vascular area was significantly increased in the 
HA gel + nV + Fn9*10 (α3/α5β1 specific) condition compared with any other group in both 
regions (Fig. 5d,e), suggesting a strong role of activated α3/α5β1 integrin binding in 
promoting the angiogenesis process.
In order to evaluate the quality of these newly formed vascular network, both their 
permeability and structure were studied. For this, Ter-119, a red blood cell marker was used 
to assess vessel permeability (Fig. 5c). The results showed a significantly reduced positive 
area for Ter-119 in α3/α5β1 specific HA hydrogels, suggesting a beneficial effect of the 
activation of α3/α5β1 in reducing VEGF induced vascular permeability (Fig. 5f). In 
addition, the morpho-analysis of tomato lectin-perfused vessels was performed by 
quantifying the number of vascular ramifications growing out of a common vascular tree. 
We found that the number of ramifications per mm2 was again significantly greater in α3/
α5β1 specific HA hydrogels (Fig. 5g). These results demonstrate for the first time that 
hydrogels with specific integrin activation can modulate vascular patterning after stroke and 
could reduce soluble VEGF induced vascular permeability.
Integrin-specific scaffold for therapeutic angiogenesis
Integrin binding is a fundamental design parameter for engineering matrices for tissue repair 
and regeneration. The incorporation of integrin binding molecules within engineered 
matrices ranges from peptides such as RGD55, to protein fragments56, and natural 
proteins57, with the primary purpose to promote cell spreading and migration within these 
matrices. However, integrin binding ligands are often overlooked as bioactive cues, capable 
of dictating morphogenesis and guiding tissue repair. Our work shows that integrin 
stimulation from engineered matrices is a morphogenic signal that can be harnessed to 
generate either a normal vasculature or a diseased vasculature depending on the integrin 
being engaged (Fig. 6).
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Methods
Recombinant fibronectin fragments
Recombinant fibronectin fragments of the 9th type III repeat (Fn III9) and 10th type III 
repeat (Fn III10) were designed to preferentially bind α3/α5β1 or αvβ3 integrin 
respectively. To achieve α3/α5β1 specificity, the thermodynamic stability of Fn III9 was 
increased through a leucine to proline point mutation at position 1408. This mutation has 
been previously shown to stabilize the integrin-binding domain of fibronectin, i.e. Fn 
III9-10, and enhance its binding selectivity to synergy-dependent β1 integrins, including 
both α5β1 and α3β125, 27, 28.To achieve αvβ3 integrin specificity, four (4) glycine residues 
were then inserted into the linker region between Fn III9 and Fn III10. The 4xGly insertion 
both physically separates the synergy (PHSRN) and RGD sites located on Fn III9 and Fn 
III10, respectively, and introduces torsional flexibility between the two domains, resulting in 
a complete disruption of α3/α5β1 integrin binding and promoting a αvβ3 integrin 
preference. Though both recombinant fragments can theoretically bind αvβ3 integrin via the 
RGD sequence, we and others consistently observe a preference of the stabilized mutant to 
bind synergy-dependent integrins, like α5β1 integrin in cell material interactions26, 29. In 
this manuscript, we called the Leu-Pro mutated, or stabilized, fragment 9*10 and the 4xGly 
insertion mutated fragment 9(4G)10. For ease of immobilization onto surfaces and 
incorporation into natural and synthetic hydrogel biomaterials both fragments were 
produced with an N-terminal cysteine residue to allow Michael type addition modifications 
and a factor XIIIa substrate sequence, consisting of residues 1–8 of the protein alpha2 
plasmin inhibitor (α2PI1-8, NQEQVSPL)30 to allow enzymatic conjugation.
The expression system for these recombinant Fn fragments has been optimized from prior 
publications (Markowski et al.) to create a high throughput production process29. The 
expression vectors were transformed into MDS™42 LowMut ΔrecA (6262) chemically 
competent cells and individual clones were picked for successive expansion and increased 
protein yields. Transformed cells were grown in 2xYT media with Kanamycin (50 μg/mL) 
and protein production was induced by addition of 1.5mM IPTG. Incubation at 37°C with 
shaking for approximately 16 hours allows maximal protein production. Cultures were then 
centrifuged and lysed via sonication and freeze-thaw cycling. Recombinant Fn9-10-
tdtomato-10 His were purified on a HisTrap nickel column (AKTSA Start, GE Healthcare) 
via affinity chromatography. Tdtomato and 10-His tag were removed by utilizing the 
thrombin cleavage site and bovine thrombin (Sigma-Aldrich) to separate the fragment and 
the tdtomato fusion protein. A Benzamidine column bound the free bovine thrombin and the 
His tag allows collection of C-terminal tdtomato in the HisTrap again and the Fn fragments 
(Fn9*10 or Fn9(4G)10) were released. The purity of Fn9-10 protein fragments was then 
analyzed by SDS-PAGE as mentioned in previous works25, 26.
Immobilization of Fn9*10 or Fn9(4G)10 on homogenous gold surface
Standard laboratory microscope glass slides were sequentially washed with acetone, 
isopropyl alcohol and methanol before gold deposition in e-beam evaporator. Deposition 
parameter: 5nm titanium at 0.3 Å/s deposition rate, followed by 30 nm gold at 0.5 Å/s 
deposition rate. Gold slides were then functionalized with 1% HS-C11-EG6-NH2(11-
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Mercaptoundecyl)hexa(ethylene glycol) amine, ProChimia Surfaces) and 99% HS-C11-
EG4-OH (11-Mercaptoundecyl)tetra(ethylene glycol), Sigma-Aldrich). A total of 100mg of 
EMCH (N-[e-Maleimidocaproic acid]hydrazide, Fisher Scientific, PI-22106) was first 
dissolved in anhydrous DMSO(Dimethyl sulfoxide) to make 50Mm stock. 5 mg/ml Heparin 
(Alfa Aesar, A16198) solution in 100mM 2-(N-morpholino)ethanesulfonic acid (MES) pH6 
buffer was then mixed with EMCH, NHS (N-Hydroxysuccinimide, Sigma-Aldrich) and 
EDC (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, Fisher Scientific) 
sequentially. Mole ratio of COOH in heparin/EMCH/NHS/EDC=1:1:1:10. The reaction 
continued for 6 hours with gentle shaking followed by dialysis. The dialyzed samples were 
then lyophilized and sent for NMR for modification verification. The modified heparin was 
then conjugated to SAMs (99% EG-OH, 1% EG-NH2) formed on gold slides via EDC/NHS 
method as previously stated. Either Fn9*10 or Fn9(4G)10 (1000ng/slide, 53.3ng/cm2) was 
incubated with the modified heparin-coated surfaces overnight at 4 °C, followed by three 
PBS washes.
ELISA on gold surface
Modified gold surfaces was Argon-dried and then assembled together with PDMS sheet that 
has two 8mm circular wells followed by 60ul/well 0.1%BSA-PBS as blocking buffer for 1 
hour at room temperature. After aspiration, 60ul/well of Anti-Fibronectin primary antibody 
(1:2000 dilution in blocking buffer, ab299, Abcam) was added for 2 hours at room 
temperature. After 3 washes using 0.05% Tween-20+PBS (washing buffer), 60ul/well of 
streptavidin-HRP (1:5000 dilution in blocking buffer, #DY998, R&D Systems) was added 
for 1hour at room temperature. After 3 washes, 60ul/well of TMB substrate (#7004L, Cell 
signaling) was added, incubated for 8 min in dark and then transferred to 96-well plates 
containing 1M H2SO4. The absorbance was measured at 450nm and normalized against 
absorbance at 550nm.
Primary cells
HUVEC cells (LONZA, CC-2519); HDF cells (Thermo Fisher Scientific, C0135C). Both 
cell types are primary and not cell lines, which were tested negative for mycoplasma, 
bacteria, yeast, fungi, HIV-1, hepatitis B and hepatitis C.
Cell Proliferation Assay
Slides immobilized with Fn9*10 or Fn9(4G)10 were washed twice with sterile PBS and then 
blew dry in cell culture hood for well assembly with 8-wells ibidi sticky-bottom device 
(ibidi, #80828). A total of 5000 HUVECs in EGM-2 stripped off fibronectin were seeded in 
each well with 2ng/ml of VEGF and the cell number was assayed after 48 hours using 
Cyquant assay. This experiment was performed 4 times on different days. Each time, at least 
8 wells were seeded and analyzed for each condition. The plot generated is from averages of 
the biological (different days) replicates. The analysis was performed blindly by a different 
observer from whom that set up the experiments.
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Cell Migration Assay
Slides immobilized with Fn9*10 or Fn9(4G)10 were washed twice with sterile PBS and then 
blew dry in cell culture hood for well assembly with PDMS sheets containing two 8mm 
holes. 5000 HUVECs pre-stained with SP-DilC18(3) lipophilic red fluorescence dye (Life 
Technologies) were seeded in each PDMS well on surface in EGM-2 w/o Fibronectin/VEGF 
medium and allowed for cell attachment for 3 hours in cell incubator. The slides were then 
transferred into incubation system of Zeiss LSM 780 confocal for 10× phase time-lapse 
tracking. In this experiment, single cell tracking was performed and each individual cell was 
considered a biological replicate. Within the two PDMS wells, two 10× regions (at least 
2mm apart) in each well were monitored via time lapse microscopy to have total of 4-time 
series of 10× images per condition. Thus, images were taken at 4 different locations over 
time span of 7 hours with 15 min interval. These 10× images time series were then divided 
into 16 equally sized square sub-regions. For each sub-region time-laps image series, one 
cell was blindly circled out and its movement was detected by automated Mathlab program. 
The graphs were directly outputted by the Mathlab program and was composed of 64 
individual cells path per condition. n=64 in each condition was used for quantification 
purpose.
2D Immunofluorescence Staining on Fragments Coated Cell Culture Plates
Glass-bottom 24-well plates were first incubated with 500μl of 2 μM Fn9*10 or Fn9(4G)10 
per well overnight. Wells were incubated with 5% BSA-PBS for 1 hour at room temperature 
before the seeding of HUVECs which were pre-starved in EBM-2 media for 6 hours. A total 
of 50000 HUVECs in EGM-2 media stripped off fibronectin were seeded in each well 
without VEGF and fixed after 18 hrs. Cell samples were first fixed in 1% PFA for 20 min, 
washed twice with PBS for 5 min. Samples were incubated at room temperature for 30min 
in blocking buffer: PBS+ 5% Normal Goat Serum. Primary antibodies were prepared as 
follows in blocking buffer: Mouse anti-αvβ3 (clone LM609, Millipore; MAB1976) – 1:100, 
Mouse anti-α5β1(clone HA5, Millipore; MAB1999) – 1:100. Samples were incubated with 
primary antibodies overnight at 4°C, followed by Secondary antibodies (1:500), rhodamine 
phalloidin (1:500) and 2μg/ml DAPI for 1 hour in the dark at room temperature. Imaging 
was performed using a Nikon C2 confocal.
2D Immunofluorescence Staining on Fragments immobilized Gold Surfaces
Slides immobilized with Fn9*10 or Fn9(4G)10 were washed twice with sterile PBS and then 
blew dry in cell culture hood for well assembly with 12-well customized white Teflon wells. 
A total of 5000 HUVECs in EGM-2 stripped off fibronectin were seeded in each well with 
or without 2ng/ml of VEGF and fixed after 24 hrs. Cell samples were first fixed in 4% PFA 
for 15 min, washed twice with PBS for 5 min each before incubating with PBS+0.1% Triton 
for 3 min. After washing the samples again with PBS, samples were incubated at room 
temperature for 30min in blocking buffer: PBS+ 2% Normal Goat Serum. Primary 
antibodies were prepared as follows in blocking buffer: Rabbit anti-mouse and human 
VEGFR-2 (Cell Signaling Technology; #2479L) – 1:200, Mouse anti-human PECAM-1 
(R&D; #BBA7) – 1:200, Monoclonal mouse anti-Vinculin antibody (Sigma-Aldrich, 
#V9131) – 1:400, Mouse anti-αvβ3 antibody (EMD Millipore, MAB1976) – 1:200. 
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Samples were incubated with primary antibodies overnight at 4°C, followed by Secondary 
antibodies (1:500), Alexa Fluor 488 phalloidin (1:500) and 2μg/ml DAPI for 1 hour in the 
dark at room temperature. Imaging was performed using a Zeiss confocal and images were 
analyzed using Image J.
Sprouting Assay with blank, full length Fibronectin, Fn9*10 or Fn9(4G)10 fibrin gels
The sprouting fibrin bead assay was performed as previously described by others57 with 
some modifications. HUVEC coated beads were resuspended at a concentration of 500 
beads/ml in 2 mg/ml fibrinogen (Fib1 or Fib3), 1 U/ml factor XIII and 0.04 U/ml aprotinin 
at a pH of 7.4 with or without 2 μM Fn9*10, 2 μM Fn9(4G)10, or 0.54 μM full length 
Fibronectin (Millipore, FC010). A total of 250 ul of this fibrinogen/bead solution was added 
to 0.16 units of thrombin in one well of glass-bottom 24-well plates. Fibrinogen/bead 
solution was allowed to clot for 5 min at room temperature and then at 37°C and 5% CO2 
for 20 min. EGM-2 w/o fibronectin was added to each well and equilibrated with the fibrin 
clot for 30 min at 37°C and 5% CO2. Medium was removed from the well and replaced with 
1 ml of fresh EGM-2 w/o Fibronectin. A total of 20,000 HDFs were plated on top of the clot 
and the medium was changed every other day. Bead assays were monitored for 7 days and 
then fixed in 4% PFA for 20 min. Samples were washed three times in PBS for 5 min each, 
blocked for 2 hours at room temperature in a blocking buffer of PBS+ 0.05% Tween-20 
+ 5% Normal Goat Serum. Samples were then stained with Alexa Fluor 488 phalloidin or 
rhodamine phalloidin (1:500) and 2μg/ml DAPI for 1 hour in the dark at room temperature. 
Imaging was performed using a Nikon C2 confocal and images were analyzed using Image 
J. At least three independent gels were evaluated per condition per sprouting experiment. 
Quantifications of at least 5 beads from each gel were analyzed (only sprouts with a length 
of one bead diameter were included). Since beads contain a small number of HUVECs that 
can vary widely in sprouting behavior, and each bead was surrounded by its own 
microenvironment, we consider each bead as an independent sprouting sample. Additionally, 
sprouting data were analyzed across experiments performed in different days taking each 
day as one biological replicate (in supplementary information). The trends from both types 
of analyses are the same.
Sprouting Assay with RGD Presence
Sprouting assay was performed as previously described in Fib3 fibrin gels with 200, 500 or 
1000 μM of α2PI1-8-RGD (H-NQEQVSPLRGDSPG-NH2, GenScript).
Anastomosis Sprouting Assay with Fn9*10 and Fn9(4G)10
The anastomosis assay was performed similarly to the sprouting assay with minor 
modifications. Briefly, EGFP-HUVEC were used to coat the dextran-coated Cytodex 3 
microcarriers. EGFP-HUVEC coated beads (500 beads/ml) were resuspeded in 2 mg/ml 
Fib3 fibrinogen, 1 U/ml factor XIII and 0.04 U/ml aprotinin, 80,000 cells/ml HDF at a pH of 
7.4 with 2 μM of Fn9*10 or Fn9(4G)10. This fibrinogen/bead solution (250 μl) was added to 
0.16 units of thrombin in one well of glass-bottom 24-well plates. Fibrinogen/HUVEC 
bead/HDF cells solution was allowed to clot for 5 min at room temperature and then at 37°C 
and 5% CO2 for 20 min. EGM-2 w/o Fibronectin was added to each well and equilibrated 
with the fibrin clot for 30 min at 37°C and 5% CO2. Medium was removed from the well 
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and replaced with 1 ml of fresh EGM-2 w/o Fibronectin and later was changed every other 
day. Bead assays were monitored for 11 days. Three independent wells were evaluated per 
condition. Imaging was performed using a Nikon C2 confocal. Tip-tip contact distribution 
from each condition were analyzed within the 170μm of working distance of 60× objective.
Flow Cytometry Analysis of to test the Efficiency of αv Blocking Functional Antibody P3G8
HUVEC cells were harvested from 25 cm2 cell culture flask using 1ml of 2mg/ml 
Collagenase (Thermo Fisher Scientific, ICN1951091) for incubation of 30min at 37°C. The 
reaction was later quenched with 1mM EDTA in PBS for 5min before centrifugation at 200g 
for 5min. 60,000 cells per well were then added to 96-well round-bottom plate (Corning, 
3365) which already contained 100 μl of serial dilution of P3G8 (Developmental Studies 
Hybridoma Bank) starting at concentration of 1μg/ml. The plate was then incubated in cell 
incubator for 30min before centrifuged at 1200rpm for 2min. 200 μl of FACS buffer (2% 
FBS in PBS) per well was then added to resuspend the cells pellet. This washing step was 
repeated twice before Goat-anti-Mouse AF488 was diluted in 1:4000 and added into the 
wells. The secondary antibody incubation was done in dark outside of incubator for 20min. 
Cells were then centrifuged and washed 3 times like described above. The final cell pellets 
were resuspended in FACS buffer. Analysis was performed using a MACS Quant VYB and 
the data was analyzed using FLOWJO. Triplicates were done for each condition with at least 
9700 events/sample. The data was gated such that the negative control had 0.5% positive 
events (Fig. S10).
Integrin Blocking Sprouting Assay
Sprouting assays were performed as previously described. For Fn9*10 gels, HUVEC beads 
were suspended at a concentration of 500 beads/ml in 2 mg/ml fibrinogen (Fib1 or Fib3), 1 
U/ml factor XIII, 0.04 U/ml aprotinin and 2 μM (high dosage) or 0.267 μM (low dosage) 
Fn9*10 at a pH of 7.4 with or without 5μg/ml of β1 integrin blocking antibody (AIIB2, 
Developmental Studies Hybridoma Bank) or α5 integrin blocking antibody (BIIG2, 
Developmental Studies Hybridoma Bank). The blocking antibody (5μg/ml) in fresh 
fibronectin-free EGM-2 medium was replenished every day.
For Fn9(4G)10 gels, HUVEC beads were suspended at a concentration of 500 beads/ml in 2 
mg/ml fibrinogen (Fib1 or Fib3), 1 U/ml factor XIII, 0.04 U/ml aprotinin and 2 μM (high 
dosage) or 0.239 μM (low dosage) Fn9(4G)10 at a pH of 7.4 with or without 5μg/ml of β3 
integrin blocking antibody (9H5, Developmental Studies Hybridoma Bank) or αv integrin 
blocking antibody (P3G8, Developmental Studies Hybridoma Bank). The blocking antibody 
(5μg/ml) in fresh fibronectin-free EGM-2 medium was replenished every day.
VE-cadherin Staining on 3D Integrin-Blocking Assay
Gel samples were first fixed in 1% PFA for 15 min, blocked for 2 hours at room temperature 
in a blocking buffer of PBS+ 0.05% Tween-20 + 5% Normal Goat Serum. Samples were 
then incubated in a primary antibody directed against VE Cadherin (Rabbit, Abcam; 
ab33168, 1:200) overnight at 4°C, followed by a secondary antibody (1:500), rhodamine 
phalloidin (1:500) and 2μg/ml DAPI for 1 hour. Imaging was performed using a Nikon C2 
confocal and images were analyzed using Image J.
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VE-cadherin Staining on 2D Fragments-Coated Surfaces
A total of 500ul of 2 μM Fn9*10 or Fn9(4G)10 in PBS buffer was added into sterile 24 well 
glass-bottom plates (MatTek Corporation) for 1 hour in cell incubator, followed by 0.1% 
heat-deactivated sterile BSA-PBS buffer for 1 hour. HUVECs cells pre-starved for 6 hours in 
EBM-2 were collected, resupspended in EGM-2 medium w/o Fibronectin either with or 
without VEGF and seeded into fragments and BSA treated wells. Cell density of 50,000 
cells per well in 24-well glass-bottom plates was used. After 12 hours, cells were fixed in 
1% PFA for 15 min and stained for VE-cadherin. Cell samples were first fixed in 1% PFA 
for 15 min, washed three times with 1XPBS for 5 min before blocked for 2 hrs at room 
temperature in blocking buffer: 1XPBS+ 0.1%BSA + 0.1% Tween-20 + 0.3M Glycine
+ 10% Normal Goat Serum. Samples were incubated in a primary antibody Rabbit anti-VE 
Cadherin (Abcam; ab3316, 1:500) overnight at 4°C, followed by a secondary antibodies 
Donkey anti-Rabbit (1:500), rhodamine phalloidin (1:500) and 2μg/ml DAPI for 1 hour. 
Imaging was performed using a Nikon C2 confocal and images were analyzed using Image 
J. At least three independent wells were evaluated per condition on a same-day experiment. 
The experiment was repeated three times on different days. Similar trend was observed. The 
data reported in the main text figures represent one of these experiments. Images were taken 
per well by a blinded observer and analyzed blindly by a different person from that who took 
the images. Grey value distributions were analyzed using Image J.
Hyaluronic Acid-Acrylate Synthesis
Sodium hyaluronan was modified to contain acrylate functionalities as previously 
described58.
Vascular Endothelial Growth Factor Nanocapsules Synthesis
Plasmin-degradable nanocapsules of VEGF (nV) wer formed through in situ radical 
polymerization of acrylate and acrylamide containing monomers and peptide crosslinkers 
around a protein core as previously described48 (Fig. S7e). Capsules with four different 
compositions (100:0, 75:25, 50:50, 25:75 L peptide:D peptide) were mixed together. The L 
to D peptide compositions were, to render the capsules degradable at different rates.
HA Hydrogel Storage Modulus Optimization
HA hydrogel was formed in 0.3M pH 8.2 HEPES buffer, following steps as below.
Tube 1: HA-ADH-Ac in HEPES buffer (ADH modification is 65.62% and Ac modification 
is 13.33%) was incubated with fibronectin fragments of for 20 min. Tube 2: Poly(ethylene 
glycol) dithiol (MW 1000, Sigma-Aldrich, #717142) and Alexa Fluor 555 C2 Maleimide 
(Thermo Fisher Scientific, #A-20346) solutions in HEPES buffer were mixed together at 
equal moles for 20 min to generate fresh SH-PEG-AF555. Tube 1 was then mixed with Tube 
2 mixture for 20 min before nanocapsules of VEGF was added. Di-cysteine modified Matrix 
Metalloprotease (MMP) (Ac-GCRDGPQGIWGQDRCG-NH2) (GenScript) sensitive 
crosslinker was added in the end to initiate gelation. Gelation was allowed for 30 min at 
37°C. To determine the storage modulus range, gels with different thiol to acrylate (R ratio) 
were tested. Pre-swelled HA hydrogels (8mm in diameter and 1mm thickness) were placed 
between 8mm (diameter) rheological discs at normal force of 0.01N using a plate-to-plate 
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rheometer (Anton paar physica mcr 301 Rheometer). The storage modulus was measured 
under constant 1% amplitude, from 10 to 0.1 rad/s angular frequency and was optimized to 
be 350Pa. Three independent gels were casted and evaluated per R ratio condition (Fig. 
S11a).
HA Gel Formula for SubQ Mice Model
HA hydrogel was synthesized as described above. Briefly, HA-ADH-Ac is dissolved into 
0.08mg/ml solution in 0.3 M HEPES buffer (pH8.2). The solution is then incubated with 
10μM Fn9*10 or Fn9(4G)10 (this amount of fibronectin fragment has been shown to 
sufficiently promote cell spreading in HA hydrogel in vitro, Fig. S11b) for 20 min. SH-PEG-
AF555, nanoVEGF, and MMP crosslinker are added sequentially. R ratio of 0.60 was used 
for animal experiment. The final composition of the hydrogel is 3.5% HA, MMP crosslinker 
3.335 mM, SH-PEG-AF555 10 μM, Fn fragments 10μM, VEGF 200ng/50μL gel, G′ = 
350Pa.
SubQ Mice Model
G*Power was first used to compute the required sample size. Using two-tailed t-test on 
previous SubQ data and high variance assumption for the tortuosity measurement, we found 
the required sample size to be within the range of 3 to 6. We choose to start with 6 samples 
(2 gel samples on each animal) per group.
All in vivo studies were conducted in compliance with the NIH Guide for Care and Use of 
Laboratory Animals and UCLA ARC standards. Gel implantation was performed as 
previously described59. At day 7, the clips closing the incision were taken off and after 2 
weeks, each mouse was injected with 100ul of 1mg/ml of isolectin GS-IB4-AF488 conjugate 
(ThermoFisher Scientific, #I21411) through the left external jugular vein before and 
sacrificed by isoflurane overdose. The implant hydrogels (total of 6 blank gels, 6 Fn9*10 
gels, 6 Fn9(4G)10 gels) were then collected and fixed in 1% PFA for 16 hours at 4°C. Due 
to the variance in sample collection process, the membrane layers attached to the implants 
were intact only for 4 gel implant per condition. Thus, for confocal imaging, only those with 
intact membranes were analyzed.
SubQ Mice Model Quantification
Samples were first imaged using a Nikon C2 confocal to visualize the superficial vascular 
network on the surface of the sample. For space filling analysis, confocal images were 
converted to binary images and analyzed using the Matlab software package. Images were 
divided into equally sized regions using window sizes of 256 pixels in length for 4×4 heat 
map images. The fraction of non-white pixels in each region was calculated and utilized to 
generate an associated heat map indicating the degree of vascular signaling present in that 
region. Color map scale bars were set in grayscale.
Light sheet microscopy was then used to image the vascular infiltration in the implanted gel. 
Briefly, fixed hydrogel samples were inserted into a transparent 6mm tube. The tubes were 
then filled with 0.3% agarose solution in PBS. After the agarose gel solidified, samples were 
fixed in position and sheet confocal images were taken at 4× magnification for whole-mount 
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samples (3–5μm step size, 6000 images total). After 3D rendering, 100μm-thick samples 
were sliced out to merge into single-plane maximum intensity projection image (none-
overlapping samples, 4 to 6 different slices from each gel sample, 6 individual implant gels 
per condition).
Ischemic Stroke Model
G*Power was first used to compute the required sample size. Using two-tailed t-test on 
previous stroke data and high variance assumption for the vessel density measurement, we 
found the required sample size to be within the range of 3 to 9. We used 7 or 8 animals per 
group.
Animal procedures were performed in accordance with the US National Institutes of Health 
Animal Protection Guidelines and the University of California Los Angeles Chancellor’s 
Animal Research Committee. Focal and permanent cortical stroke was induced by a middle 
cerebral artery occlusion (MCAo) on young adult C57BL/6 male mice (8–12 weeks) 
obtained from Jackson Laboratories. The male mice were chosen because females of this 
age have a complete and cyclic menstruations. The increased systemic inflammation that is 
associated with their cycle could interfere with the results of the experiments. Briefly, under 
isoflurane anesthesia (2–2.5% in a 70% N2O/30% O2 mixture), a small craniotomy was 
performed over the left parietal cortex. One anterior branch of the distal middle cerebral 
artery was then exposed, electrocoagulated and cut. Body temperature was maintained at 
36.9 ± 0.4 °C with a heating pad throughout the operation. In this model, ischemic cellular 
damage is localized to somatosensory and motor cortex60.
Brain Hydrogel Transplantation
No randomization was used in this experiment. In order to avoid any confusion, all the 
animals from a cage were injected with the same treatment. Each cage represented one 
condition, with 2 cages per condition since the n is superior to 4, the max number of animal 
allowed per cage. Animals were labeled with their condition and a number attributed in the 
order of surgery. Five days later, HA hydrogel precursor (see Table for composition) was 
loaded into a 25 μl Hamilton syringe (Hamilton, Reno, NV) connected to a syringe pump. 
The solution was then injected in liquid form directly into the stroke cavity using a 30-gauge 
needle at stereotaxic coordinates 0.26 mm anterior/posterior (AP), 3 mm medial/lateral 
(ML), and 1 mm dorsal/ventral (DV) with an infusion speed of 1 μl/min. The needle was 
withdrawn from the mouse brain immediately after the injection was complete. The final 
composition of the hydrogel is 3.5% HA, MMP crosslinker 3.335 mM, Fn fragments 10μM, 
VEGF 200ng/6μL gel, G′ = 350Pa.
Ten days following the hydrogel transplantation, animals injected with fibronectin fragment 
(Vs+ Fn9*10, nV+Fn9*10 and nV+Fn9(4G)10) containing hydrogels were perfused with 
DyLight 594 labeled Lycopersicon Esculentum (Tomato) Lectin (Vector Laboratories, # 
DL-1177) through the left through external jugular vein and then sacrificed by isoflurane 
overdose. Other mice conditions (No gel, HA-RGD and Vs+HA-RGD) were perfused with 
4% PFA and sacrificed.
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Brain tissue processing
Mice brains were harvested and post-fixed in 4% PFA overnight or perfused with PFA 
before harvesting, then cryoprotected in 30% sucrose in phosphate buffer for 24 hours and 
frozen. Tangential cortical sections of 30 μm-thick were sliced using a cryostat and directly 
mounted on gelatin-subbed glass slides. Brain sections were then washed in PBS and 
permeabilized and blocked in 0.3% Triton and 10% Normal Donkey Serum before being 
immunohistochemically stained. The primary antibody Rat anti-Ter-119 (R&D Systems, 
#MAB1125, 1:200), Rabbit anti-Glut-1 (Glucose Transporter1, Abcam, 1:400) or Rabbit 
anti-Fibronectin (Millipore, AB2040, 1:200) were incubated overnight at +4°C followed by 
secondary antibodies Donkey anti-rat and rabbit- AF488 (Thermo Fisher Scientific, 1:200) 
for 1 hour at room temperature. After 3× 10 minute washes in PBS, the slides were 
dehydrated in ascending ethanol baths, dewaxed in xylene and coverslipped over fluorescent 
mounting medium (Dako). Once brain sections were stained, a different experimenter 
attributed a random number to each animal to keep the main experimenter blind. The images 
were blindly taken and analyzes were performed without identifying the different samples to 
the different conditions.
Microscopy and Morphoanalysis
Analyses were performed on microscope images of 3 coronal brain levels at +0.80 mm, 
−0.80 mm and −1.20 mm according to bregma, which consistently contained the cortical 
infarct area. Each image represents a maximum intensity projection of 10 to 12 Z-stacks, 
0.85μm apart, captured at a 20× magnification with a Nikon C2 confocal microscope using 
the NIS Element software. Each n represents one mouse.
To quantify the vascular bed in the no gel and gel conditions, Glut-1 stained only or Gut-1 
plus tomato lectin in tomato lectin-perfused animals were quantified. Tomato lectin alters 
Glut-1 staining such that in lectin-perfused animals the combination of both stains reveals 
the vascular bed the same as Glut-1 alone in tomato lectin-unperfused animals (Fig. S9b).
The vascular area—The vascular area (stained by Glut-1 only or by both tomato lectin 
and Glut-1) in the infarct and peri-infarct areas was quantified in 8 randomly chosen regions 
of interest (ROI) of 0.3 mm2 in both regions. In each ROI, the positive area was measured 
using pixel threshold on 8-bit converted images (ImageJ v1.43, Bethesda, Maryland, USA) 
and expressed as the area fraction of positive signal per ROI. Values were then averaged 
across all ROI and sections, and expressed as the average positive area per animal.
The evaluation of perfused vascular ramifications—The evaluation of perfused 
vascular ramifications allows for a quantitative analysis of the vessel architecture, by 
counting manually the number of branching points on positively tomato lectin perfused 
vessels of the peri-infarct per mm2.
Statistical Analysis
Statistical analyses were performed using Prism (GraphPad, San Diego, CA). Brown-
Forsythe test was performed to test the variance similarity between the groups that are being 
statistically compared. The variance is similar between the groups that are being statistically 
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compared. Data were analyzed using a one-way analysis of variance (ANOVA) followed by 
a Tukey post-hoc test and a 95% confidence interval.
For 2D VE-cadherin staining analysis (n=3) and stroke model quantification (minimum 
n=5), two-tailed unpaired test was used when only two groups were compared. The results 
are expressed as mean ± SD. Single, double, triple and quadruple asterisks represent p < 
0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively. A p value < 0.05 was considered 
statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Endothelial cell sprouting in αvβ3 specific matrices displays clustered branches
(a) HUVEC sprouting in FXIIIa stabilized fibronectin containing fibrin gel (Fib1) and 
fibronectin depleted fibribrin gel (Fib3). Scale bar: 100 μm. (b,c) Quantification of sprout 
number and branch points per bead in Fib3 matrices. (d,e) Quantification of sprout number 
and branch points per bead in Fib1 matrices. (f) Representative images and 3D views of 
HUVEC branch structures in both αvβ3 and α3/α5β1 specific Fib3 matrices. Intra-loop and 
intra-joint branch structures were observed in αvβ3 specific matrices while organized 
branch structures were observed in α3/α5β1 specific matrices. Scale bar: 50 μm. (g) 
Quantification of branch clusters per bead and (h) branch cluster number per sprout. Blank = 
blk = no fibronecitn fragment added, α3/α5β1 specific matrices = gel + 2μM Fn9*10, αvβ3 
specific matrices = gel + 2μM Fn9(4G)10, Fn matrices = Fib3 gel + 1μM Fn. For all 
quantifications n ≥ 15 HUVEC coated beads, from 3 independent gels. Each bead is treated 
as its own independent sample. Statistical analyses were performed using Prism (GraphPad, 
San Diego, CA). Brown-Forsythe test was performed to ensure that the variance of the data 
is similar between the groups that are being statistically compared. Data were analyzed 
using a one-way analysis of variance (ANOVA) followed by a Tukey post-hoc test and a 
95% confidence interval. All plots represent mean ± SD. * and ** indicate P < 0.05 and P < 
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0.01, respectively. An alternative statistical analysis for this data treating experiments 
performed on different days as the independent sample can be found on Figure S3.
Li et al. Page 23
Nat Mater. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Endothelial cell sprount clustering is partially rescued with αv blocking
(a) HUVEC sprouting in the presence of integrin αv, α5, β1 or β3 (5μg/ml changed daily) 
blocking antibodies. Blocking α5, β1 or β3 completely blocks sprouting, while blocking αv 
does not. α3/α5β1 specific matrices = gel + 2μM Fn9*10, αvβ3 specific matrices = gel 
+ 2μM Fn9(4G)10. Scale bars, 100 μm. (b) comparison of branch cluster occurrence with 
and without αv blocking (n=51 HUVEC coated beads from three independent gels). (c) 
Images showing HUVEC sprouts in RGD (1000μM) modified FXIIIa stabilized Fn depleted 
fibrin matrices. RGD modified matrices promote HUVEC sprouting and branch cluster 
formation. Scale bar: 50 μm (d,e) Quantification of HUVEC sprouting in RGD modified Fib 
3 matrices at different concentrations. (f) Quantification of branch clusters per bead. For 
quantification n ≥ 15 HUVEC coated beads, from 3 independent gels. Each bead is treated 
as its own independent sample. Statistical analyses were performed using Prism (GraphPad, 
San Diego, CA). Brown-Forsythe test was performed to ensure that the variance of the data 
is similar between the groups that are being statistically compared. Data were analyzed 
using a one-way analysis of variance (ANOVA) followed by a Tukey post-hoc test and a 
95% confidence interval. All plots represent mean ± SD. *,*** and **** indicate P < 0.05, P 
< 0.001 and P < 0.0001.
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Figure 3. αvβ3 integrin engagement disrupts VE-cadherin in HUEVEs
(a) Microscopic analysis of VE-cadherin distribution for HUVECs seeded on surfaces 
modified with α3/α5β1 or αvβ3 specific surfaces < 24-hours after plating. Scale bar: 50 μm. 
(b) Quantification of VE-Cadherin to nuclei positive area ratio for HUVECs seeded on 
surfaces modified with α3/α5β1 or αvβ3 specific surfaces < 24-hours after plating. 
Quantification was performed from 3 independent cultures performed at three different 
times. Statistical analyses were performed using Prism (GraphPad, San Diego, CA) using a 
two-tailed unpaired t-test. Plot represents mean ± SD. ** indicate P < 0.01. (c) Grey value 
distribution analysis for 3 random cell-cell junctions on α3/α5β1 specific surface from (a). 
(d) Grey value distribution analysis for 3 random cell-cell junctions on αvβ3 specific surface 
from (a). (e) Microscopic analysis of VE-cadherin signals for HUVECs seeded in α3/α5β1 
specific matrices = gel + 2μM Fn9*10, αvβ3 specific matrices = gel + 2μM Fn9(4G)10, and 
αvβ3 specific matrices + αv blocking antibody = gel + 2μM Fn9(4G)10 + αv blocking 
antibody (5μg/ml changed daily). Arrows represent reduced and missing VE-Cadherin signal 
while stars represent coherent and clear VE-Cadherin signal on sprout shunts and cell-cell 
junctions. Scale bar: 100 μm (whole bead) and 50 μm (sprouts).
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Figure 4. Modulation of vascular patterning in skin using integrin specific hydrogels
a, A modified Matrigel plug assay using bioengineered hyaluronic acid (HA) hydrogels was 
utilized to assess angiogenesis in mice. b, Images of vessels on normal mouse skin. Scale 
bars, 200 μm. c, Images of isolectin-modified vessels at the surface of the implant 2 weeks 
after implantation. Scale bar, 200 μm. d, Representative ×40 images of vessels on the surface 
of α3/α5β1-specific and αvβ3-specific HA matrices. Scale bar, 50 μm. e, Heat map analysis 
of vessel distribution on the surfaces of blank, α3/α5β1-specific and αvβ3-specific matrices 
(n = 4 individual implants). Darker box indicates higher vessel density in that region while 
white indicates the absence of vessels. Plot represents the histogram of grey values. Blank 
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gel: HA gel; α3/α5β1-specific matrices: HA gel + 10 μM Fn9*10 + 200 ng VEGF 
nanocapsules; αvβ3-specific matrices: HA gel + 10 μM Fn9(4G)10 + 200 ng VEGF 
nanocapsules. f, Vessel tortuosity comparison among blank, α3/α5β1-specific and αvβ3-
specific conditions (n = 4 implants). Statistical analyses were performed using Prism 
(GraphPad). The Brown–Forsythe test was performed to ensure that the variance of the data 
is similar between the groups that are being statistically compared. Data were analysed using 
a one-way analysis of variance followed by a Tukey post hoc test and a 95% confidence 
interval. All plots represent mean s.d., and ** indicates P < 0.01.
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Figure 5. Integrin specific hydrogels modulate vascular patterning and permeability after stroke
A middle cerebral artery occlusion ischaemic stroke model was utilized to look at the effects 
of injected integrin-specific HA matrices on stroke repair 10 days post-injection (injection 
was performed 5 days post-stroke). a, Fibronectin location in normal and stroke brain 15 
days post-stroke. Scale bars, 50 μm. b, Schematic illustration of the hydrogel injected into 
the mouse brain after stroke. VEGF nanocapsules (nV) were designed to slowly release 
VEGF. c, Fluorescent microscopy showing brain vasculature in both the infarct and peri-
infarct (stained for Glut-1 or Glut-1 plus tomato lectin intravascular perfusion) as well as 
leaked red blood cells (stained for Ter-119). The asterisk indicates the stroke site while the 
white dashed curve indicates the boundary between the infarct (stroke site) and peri-infarct 
(the area adjacent to the stroke site). Scale bars, 100 μm. d,e, Quantification of the total 
vessel area (perfused and not prefused) in the infarct (inside the stroke) and peri-infarct 
(around the stroke) areas. f, Quantification of Ter-119-positive red blood cell area. g, The 
morpho-analysis of growing vessels in the peri-infarct area for vessel ramification. All plots 
represent mean ± s.d. Each dot in the plots represents an individual mouse. Statistical 
analyses were performed using Prism (GraphPad). Data in d,e were analysed using a one-
way analysis of variance followed by a Tukey post hoc test and a 95% confidence interval. 
Data in f,g were analysed using a two-tailed unpaired test. *, ** and *** indicate P < 0.05, P 
< 0.01 and P < 0.001; NS, not significant.
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Figure 6. 
α3/α5β1 and αvβ3 integrin-specific materials regulate vascular patterning in vitro and in 
vivo
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